Provided by Tiger Trade Technology Pte. Ltd.

Alexander's

236.10
-2.8000-1.17%
Post-market: 236.100.00000.00%18:46 EDT
Volume:28.08K
Turnover:6.66M
Market Cap:1.21B
PE:42.93
High:240.77
Open:236.88
Low:235.24
Close:238.90
52wk High:260.84
52wk Low:189.05
Shares:5.11M
Float Shares:2.13M
Volume Ratio:0.55
T/O Rate:1.32%
Dividend:17.99
Dividend Rate:7.62%
EPS(TTM):5.50
EPS(LYR):5.50
ROE:19.74%
ROA:3.32%
PB:11.05
PE(LYR):42.96

Loading ...

Alexander's Q4 Adjusted Ffo per Share USD 2.43

THOMSON REUTERS
·
Feb 09

Alexander's Q4 Revenue USD 53.255 Million

THOMSON REUTERS
·
Feb 09

Alexander's Q4 FFO $2.43 Misses $3.02 Estimate, Sales $53.255M Miss $53.400M Estimate

Benzinga
·
Feb 09

Alexander's Inc. meldet für das Gesamtjahr 2025 einen Rückgang der Mieterlöse um 5,8 Prozent auf 213,18 Mio. USD

Reuters
·
Feb 09

ALX Oncology Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 05

Alexander's Keeps Quarterly Dividend at $4.50 a Share, Payable Feb. 27 to Shareholders of Record on Feb. 17

MT Newswires Live
·
Feb 05

Alexander's Inc. zahlt Quartalsdividende von 4,50 US-Dollar je Aktie

Reuters
·
Feb 05

Alexander's Inc. Declares $4.50 Quarterly Dividend

Reuters
·
Feb 05

Earning Preview: Alexander's Q4 revenue is expected to decrease by 3.26%, and institutional views are limited and cautious

Earnings Agent
·
Feb 02

What Atlas Arteria (ASX:ALX)'s Q4 Toll Revenue Growth Means For Shareholders

Simply Wall St.
·
Feb 02

ALX Oncology announces major underwritten public equity offering

TIPRANKS
·
Jan 30

ALX Oncology Announces Pricing of Underwritten Offering

GlobeNewswire
·
Jan 30

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

GlobeNewswire
·
Jan 30

ALX Oncology Expands Inducement Equity Plan for Hiring

TIPRANKS
·
Jan 22

Alexander's Inc. Publishes Update to Financial Calendar

Reuters
·
Jan 21

ALX Oncology first patient dosed in Phase 2 ASPEN-09-Breast trial

TIPRANKS
·
Jan 08

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

GlobeNewswire
·
Jan 08

Alexander’s Completes Restructuring of Retail Loan at 731 Lexington Avenue

GlobeNewswire
·
Dec 29, 2025

Alexander’s (ALX) Valuation After Rego Park II Refinancing and New $175 Million Interest-Only Loan

Simply Wall St.
·
Dec 11, 2025

Alexander’s Completes $175 Million Refinancing of Rego Park Ii

THOMSON REUTERS
·
Dec 09, 2025